Please assess the completion status of the following clinical trial:

Trial Title: Study of Subcutaneous Golimumab in Chinese Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Diagnosis of rheumatoid arthritis for at least 6 months~* Be on a stable dose of methotrexate for 4 weeks~* Have at least 4 swollen and 4 tender joints~Exclusion Criteria:~* Prior exposure to biologic anti-TNFalpha agents~* Inflammatory diseases other than rheumatoid arthritis~* Treatment with Disease Modifying Anti-rheumatic drug (DMARDs)/systemic immunosuppressives other than methotrexate during the 4 weeks prior to the first administration of study agent~* History of, or ongoing, chronic or recurrent infectious disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Golimumab + methotrexate (MTX) (Type: EXPERIMENTAL): Participants will receive golimumab 50 mg as subcutaneous (SC) (under the skin) injections administered every 4 weeks for up to 48 weeks. In addition, participants will receive a stable dose of MTX.
- Placebo + methotrexate (MTX) (Type: EXPERIMENTAL): Participants will be administered Placebo SC injections at Weeks 0, 4, 8, 12, 16, and Week 20 followed by golimumab 50 mg SC injections at Week 24 and every 4 weeks thereafter through Week 48. In addition, participants will receive a stable dose of MTX.

Based on this trial design, predict the completion outcome and termination type (if applicable).